Healthy
Conditions
Brief summary
Evaluation of safety, tolerability and pharmacokinetics of multiple rising oral doses of BI 44370 TA in healthy male and female volunteers
Interventions
DRUGBI 44370 TA
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs, 12-lead ECG, clinical laboratory tests * Age ≥21 and Age ≤50 year * BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index) * Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion criteria
* Any finding of the medical examination (including vital signs and ECG) deviating from normal and of clinical relevance * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial * Participation in another trial with an investigational drug within two months prior to administration or during the trial * Smoking (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (more than 40 g/day) * Drug abuse * Blood donation (more than 100 mL within four weeks prior to administration or during the trial) * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to comply with dietary regimen of trial site * A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms) * A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | up to 36 days |
| Number of patients with clinically relevant findings in vital signs | up to 7 days after last drug administration |
| Number of patients with clinically relevant findings in 12-lead ECG (electrocardiogram) | up to 7 days after last drug administration |
| Number of patients with clinically relevant laboratory findings | up to 7 days after last drug administration |
| Assessment of tolerability by investigator on a 4-point scale | up to 7 days after last drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Terminal half-life of the analyte in plasma (t1/2) for several time points | up to 4 days |
| Mean residence time of the analyte in the body after p.o. administration (MRTpo) for several time points | up to 4 days |
| Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for several time points | up to 4 days |
| Apparent volume of distribution during the terminal phase λz following an extravascular administration (Vz/F) for several time points | up to 4 days |
| Amount of analyte that is eliminated in urine from zero to 24 h after drug administration (Ae0-24) for several time points | up to 4 days |
| Maximum measured concentration of the analyte in plasma (Cmax ) for several time points | up to 4 days |
| Renal clearance of the analyte from zero to 24 h after drug administration (CLR,0-24) for several time points | up to 4 days |
| Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss) | up to 4 days |
| Accumulation ratio (RA) based on Cmax for several time points | up to 4 days |
| RA based on AUC for several time points | up to 4 days |
| Linearity index (LI) of the analyte in plasma | up to 4 days |
| Fraction of analyte eliminated in urine from zero to 24 h after drug administration (fe0-24) for several time points | up to 4 days |
| Time from dosing to maximum measured concentration of the analyte in plasma (tmax) for several time points | up to 4 days |
| Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC) for several time points | up to 4 days |
| The percentage of the AUC 0-∞ that is obtained by extrapolation (%AUCtz-∞) for several time points | up to 4 days |
| Terminal rate constant in plasma (λz) for several time points | up to 4 days |
Outcome results
None listed